Comparison of the Diagnostic Accuracy of 3D Volume Acquisition MRI With CT in Staging Colonic Cancer
Recruitment status was Recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to determine whether MRI is more accurate than CT in determining the T stage, N stage, depth of tumour invasion and extra mural venous invasion (EMVI) preoperatively in colon cancer.
| Condition |
|---|
|
Colon Cancer |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Retrospective |
| Official Title: | Comparison of the Diagnostic Accuracy of 3D Volume Acquisition MRI With CT in Staging Colonic Cancer |
- The primary endpoint will be the accuracy of MRI and CT in determining T stage using histology as the gold standard, on a per patient basis. [ Designated as safety issue: No ]
- Secondary endpoints will be the accuracy of CT and MRI in determining N stage, depth of invasion beyond the muscularis propria, and EMVI. [ Designated as safety issue: No ]
- We will also compare the accuracy of 1.5T against 3.0T MRI scans, and T2 weighted against T1 weighted images [ Designated as safety issue: No ]
| Estimated Enrollment: | 62 |
| Study Start Date: | August 2010 |
| Estimated Study Completion Date: | September 2011 |
| Estimated Primary Completion Date: | September 2011 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
|
colon cancer
patients undergoing treatment for colon cancer
|
Detailed Description:
The patient will proceed with their usual colon cancer assessment and treatment, including colonoscopy with biopsy and histology and preoperative CT chest abdomen and pelvis. In addition, patients who enroll in the study will have 2 preoperative MRIs of their abdomen and pelvis performed. One of these will be performed on a 1.5T and the other will be performed on a 3.0T MRI scanner. We will use 20mg of IM buscopan to reduce bowel mobility for each scan. A coronal scout scan will be taken to identify the tumour and select the target volume. IV gadolinium (a contrast agent routinely used in MRI scans to help identify different tissues) will be administered, and a 3D VIBE scan (T1 weighted) will be performed of the target volume. The liver will also be imaged at this time to look for liver metastases. A T2 weighted 3D volume acquisition will then be obtained of the target volume containing the tumour (and its lymphatic drainage).
The MRI will be independently reported by an expert without knowledge of the results of any other investigations. The results of the MRI scan will then be made available to the clinical team. The patient will then proceed as normal with any other investigation which the clinical team feel is necessary, and be treated as normal for their colon cancer. The patient will proceed with their surgery as normal, and the specimen removed at the time of the operation will be examined in the pathology laboratory to determine the exact stage of the cancer.
The accuracy of CT and MRI in staging colon cancer will then be determined against the reference standard provided by the histology examination.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
patients with colon cancer
Inclusion Criteria:
- patients undergoing treatment for colon cancer
- patients undergoing primary surgery for colon cancer and who do not require neo-adjuvant therapy on the basis of their pre-operative CT
Exclusion Criteria:
- age <18
- unable to consent
- consent withheld or withdrawn
- Unable to have an MRI (e.g pacemaker, metal implant)
- Allergy or contraindications to busocopam, gadolinium, small bowel contrast agent
Contacts and Locations| Contact: Dr Gina Brown | 02086613964 | gina.brown@rmh.nhs.uk |
| Contact: Dr Christopher Hunter | chris_j_hunter@hotmail.com |
| United Kingdom | |
| The Royal Marsden NHS Foundation Trust | Recruiting |
| Sutton, Surrey, United Kingdom, SM2 5PT | |
| Contact: Dr Gina Brown 02086613964 gina.brown@rmh.nhs.uk | |
| Contact: Dr Christopher Hunter chris_j_hunter@hotmail.com | |
| Principal Investigator: Dr Gina Brown | |
| Principal Investigator: | Dr Gina Brown | Royal Marsden NHS Foundation Trust |
More Information
No publications provided
| Responsible Party: | Dr Gina Brown, Royal Marsden NHS Foundation Trust |
| ClinicalTrials.gov Identifier: | NCT01187641 History of Changes |
| Other Study ID Numbers: | CCR3370 |
| Study First Received: | August 23, 2010 |
| Last Updated: | August 26, 2010 |
| Health Authority: | United Kingdom: Research Ethics Committee |
Keywords provided by Royal Marsden NHS Foundation Trust:
|
cancer, colon, MRI scan |
Additional relevant MeSH terms:
|
Colonic Neoplasms Colorectal Neoplasms Intestinal Neoplasms Gastrointestinal Neoplasms Digestive System Neoplasms Neoplasms by Site |
Neoplasms Digestive System Diseases Gastrointestinal Diseases Colonic Diseases Intestinal Diseases |
ClinicalTrials.gov processed this record on May 16, 2013